Other
Dec 2023Science reported backlash from the Psychiatric Genomics Consortium over Orchid’s use of research data for embryo polygenic screening; the group said its data-use terms were violated, and Orchid denied improper use.
SourceAI-powered EHR for independent mental health professionals
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Orchid is a San Francisco-based reproductive technology company offering CAP/CLIA-certified whole-genome embryo screening for IVF and preconception genetic testing to help prospective parents assess monogenic and polygenic disease risk.
Primary product
Whole Genome Embryo Screening / Embryo Report (PGT-WGS)
Founded
2020
Headquarters
San Francisco, California, United States
Team size
20-30
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Reproductive genetics / IVF embryo screening / clinical genetic testing
Offices
Palo Alto, California, United States
Business model
laboratory-developed test
per-embryo pricing
clinic-mediated B2B2C testing
preconception genetic counseling
Funding
Stage
Series A
Total raised
$16.5M
Latest round
Series A · Dec 2023
Latest amount
$12M
Dec 2023 · Prometheus Fund
Aug 2022
Apr 2021 · Refactor Capital
People & investors
Leadership
Founder and CEO
Executive Vice President, Medical Director
Head of Engineering
Director of Clinical Genetics & Product
Lead Bioinformatics Scientist
Medical Laboratory Director
Director of Clinical Partnerships, West
Investors
Amjad Masad
Anne Wojcicki
Balaji Srinivasan
Boom Capital
Brian Armstrong
Carlos Bustamante
Conviction Partners
Day One Ventures
Dylan Field
Elad Gil
Fidji Simo
Fred Ehrsam
George Church
Jed McCaleb
Kevin Hartz
Mario Schlosser
Nat Turner
Olive Capital
Pebblebed
Prometheus Fund
Refactor Capital
Starbloom Capital
Village Global
Vivek Garipalli
Work & culture
Mission-driven, low-ego team of optimistic builders focused on helping families have healthy babies and extending the next generation’s healthspan.
Work style
Flexible
Compensation
Orchid’s careers page advertises competitive compensation with base salary, equity, and generous benefits.
Benefits
Remote-friendly roles
Competitive compensation
Base salary plus equity
Generous benefits
Opportunity to influence engineering, product, and company direction
Product & market
Pricing
Per-embryo screening; Orchid’s clinician page lists standard Preimplantation Whole-Genome Sequencing at $2,500 per embryo.
Differentiators
- —Sequences over 99% of an embryo’s genome
- —Combines PGT-A, PGT-M, PGT-SR, PGT-P, and whole-genome analysis in one workflow
- —Screens for both monogenic conditions and genetic risk scores
- —Includes board-certified genetic counseling
- —CAP and CLIA certified
- —Operates as a clinician-ordered IVF workflow
Technology
Google Cloud
Lockbox LIMS
React
React Native
TypeScript
JavaScript
Python
HTML
CSS
Redux
Figma
Zoho
Ramp
Adobe Creative Suite
Palantir
Illumina
PCR
Snakemake
AWS ParallelCluster
Slurm
Customers
prospective parents
couples undergoing IVF
fertility clinics
IVF centers
clinicians
patients seeking genetic counseling
Competitors
traditional IVF genetic testing / PGT labs
Nucleus Genomics
Heliospect Genomics
other embryo-screening startups
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
35.5K
Traffic estimate as of Jun 2026
Signals & risks
Other
Jul 2025Major 2025 coverage in The Washington Post/MSN highlighted ongoing controversy over Orchid’s embryo screening, including ethics, scientific skepticism, and concerns about polygenic risk prediction accuracy.
SourceLatest news
Fast Company · Sep 2025
A deep feature on Orchid and embryo screening, framing the company as part of the broader Silicon Valley fertility-tech wave and discussing its controversial polygenic risk approach.
The Washington Post / MSN · Jul 2025
A wide-ranging report on Orchid’s embryo screening, its use by wealthy tech families, and the ethics and scientific criticism surrounding polygenic selection.
CNBC · May 2025
Video interview covering Orchid’s screening process, pricing, nationwide availability outside New York, and the company’s push to prevent genetic disease before birth.
The New York Times · Apr 2025
An opinion feature discussing Orchid’s embryo screening, polygenic risk scores, and the broader debate over reproductive choice and embryo selection.
CNBC · Dec 2023
Launch coverage for Orchid’s whole-genome embryo sequencing test, including the $2,500-per-embryo price and the $12 million funding announcement.
Jobs and careers at Orchid
0 jobs at Orchid
No open positions
Check back later for new openings